Capital Markets
Capital Markets Insights
Research notes on earnings, market structure, and financial statements. Each piece starts with the conclusion, then lays out the evidence and implications.
2026-07-21
%22%2F%3E%0A%20%20%3Ccircle%20cx%3D%22220%22%20cy%3D%22150%22%20r%3D%22180%22%20fill%3D%22%2322d3ee%22%20fill-opacity%3D%220.12%22%2F%3E%0A%20%20%3Ccircle%20cx%3D%221010%22%20cy%3D%22130%22%20r%3D%22220%22%20fill%3D%22%2338bdf8%22%20fill-opacity%3D%220.08%22%2F%3E%0A%20%20%3Ccircle%20cx%3D%22920%22%20cy%3D%22520%22%20r%3D%22170%22%20fill%3D%22%2322d3ee%22%20fill-opacity%3D%220.06%22%2F%3E%0A%20%20%3Cpath%20d%3D%22M140%20430h920%22%20stroke%3D%22url(%23line)%22%20stroke-width%3D%2212%22%20stroke-linecap%3D%22round%22%2F%3E%0A%20%20%3Cpath%20d%3D%22M220%20360c120-150%20260-220%20380-220s260%2070%20380%20220%22%20fill%3D%22none%22%20stroke%3D%22%2367e8f9%22%20stroke-opacity%3D%220.5%22%20stroke-width%3D%2216%22%20stroke-linecap%3D%22round%22%20stroke-linejoin%3D%22round%22%2F%3E%0A%20%20%3Cpath%20d%3D%22M300%20398h600%22%20stroke%3D%22%2394a3b8%22%20stroke-opacity%3D%220.24%22%20stroke-width%3D%228%22%20stroke-linecap%3D%22round%22%2F%3E%0A%20%20%3Ctext%20x%3D%22220%22%20y%3D%22510%22%20fill%3D%22%23e2e8f0%22%20fill-opacity%3D%220.7%22%20font-family%3D%22Arial%2C%20Helvetica%2C%20sans-serif%22%20font-size%3D%2238%22%20letter-spacing%3D%228%22%3EINSIGHTS%3C%2Ftext%3E%0A%3C%2Fsvg%3E)
Cardinal Health Buys AdaptHealth Diabetes Unit + Strive Medical for $360M Cash — Home-Care Roll-Up Continues
On July 20, 2026, Cardinal Health announced definitive agreements to acquire AdaptHealth's Diabetes Health business (~$235M cash) and Strive Medical — a DME supplier serving 20,000+ patients — for a combined ~$360M in cash. The deals expand Cardinal Health's Cardinal at-Home Solutions segment, deepening its position in diabetes supplies and durable medical equipment. AdaptHealth framed the divestiture as sharpening focus on its core sleep, respiratory, and HME businesses.
Jersey Mike’s IPO at up to $7.94B is a franchise-math bet: valuation hinges on sustaining high AUV while Blackstone sells into the public market
Jersey Mike’s disclosed IPO terms of 43.5 million shares in a $21–$25 range, targeting up to a $7.94B valuation and up to $1.09B of proceeds. The core investor story is not restaurant-level earnings—it’s franchise royalty economics backed by very high systemwide sales per unit ($4.217B systemwide in fiscal 2025) and an asset-light footprint (only 36 company-owned stores out of 3,300). For Blackstone, the deal is also a classic PE exit: a public listing that monetizes control while keeping upside tied to continued store growth (including an earn-out tied to reaching 4,000 global stores).
![Brookfield+[CPP Investments] to Take LXP Industrial Private for $5.2B—Industrial REIT M&A Is Pricing Control, Not Just Rent insight cover](https://images-1379091077.cos.na-ashburn.myqcloud.com/DEV/insights/covers/20260721_lxp_brookfield_cpp_acquisition_2026_360px.png)
Brookfield+[CPP Investments] to Take LXP Industrial Private for $5.2B—Industrial REIT M&A Is Pricing Control, Not Just Rent
Brookfield Asset Management and CPP Investments agreed to buy LXP Industrial Trust in an all-cash deal valued at about $5.2B (including net debt) at $61.20/share, a double-digit premium with a 40-day go-shop window. Using LXP’s recent fundamentals, the offer implies a rich takeover multiple versus the last several years’ revenue and cash flow—suggesting buyers are paying for asset/tenancy control and a path to recapitalize rather than buying a cheap stream of rents. For investors, this deal is a real-time “private-market bid” read-through to where industrial REIT control premium (and execution risk) is heading in 2H 2026.
14-Day TRO Forces Paramount Skydance to Pause the $110B WBD Deal—The Mega-Media M&A Era’s First Real Court Litmus Test
On July 20, 2026, a U.S. district judge granted a 14-day TRO blocking Paramount Skydance’s $110B acquisition of Warner Bros. Discovery (through at least an Aug. 3 hearing). The order turns what had been “regulatory risk” into an economic squeeze: WBD shares dropped ~3.8% that day and the deal’s structure includes a $0.25-per-share ticking fee if the close slips past Sept. 30. For investors, the core question is whether this is a short delay—or the opening move in a longer antitrust fight over wide-release theatrical distribution and cable power.
Reformation’s IPO Terms Price a “Profitable DTC” Outfitter for Public Markets—But the Margin Story Still Hinges on Tariffs and Scale
Reformation’s ref S-1/A sets a $15.00–$17.00 range for a roughly $225M raise on $507.1M of 2025 revenue and $12.6M net income, with ~90% of sales from direct-to-consumer. The filing’s most investment-relevant detail isn’t the DTC mix—it’s how much reported gross margin and operating leverage swing around tariff-driven costs/refunds and store expansion discipline. If Reformation can convert store growth into steadier margins, the “profitable sustainable DTC” thesis looks investable; if not, the valuation can compress fast even with positive net income.
Scribe Therapeutics’ $100M IPO Is the First Public “Pure-Play CRISPR Risk Read” of 2H 2026—And It’s Valuing Epigenetic Gene Editing Like a Clinical-Stage Bet
Scribe Therapeutics (Scribe Therapeutics) set Nasdaq IPO terms for 7.15M shares at $13–$15, seeking about $100M at the low end and up to $107.2M at the top, with Sanofi participating in a concurrent purchase. The S-1 frames its core value creation around early, in-human data for its lead epigenetic CRISPR program (Scribe Therapeutics STX-1150]) and preclinical progress for two lipid-risk follow-ons funded partly by CIRM grants. For investors, the key question isn’t just CRISPR’s science—it’s whether public markets will underwrite early-stage execution risk after the post-2024/25 biotech window reopened.
2026-07-20
Databricks' $188B Coatue-Led Round Resets the Private-AI Ceiling: What a 40% Markup in Six Months Says About the Enterprise Data Stack
On July 17, 2026, Databricks signed a term sheet for a strategic funding round led by Coatue that values the data/AI platform at $188B — a roughly 40% step-up from its ~$134B valuation in December 2025. The round totals about $3B from new and existing investors and is expected to close later this summer. It comes on the heels of a separate ~$5B raise earlier in 2026 and stretches Databricks' lead as the most valuable non-foundation-model AI private company, sharpening questions about IPO timing, AI infrastructure economics, and the relative pricing of public SaaS peers.
India's Private Banks Slump 5% as HDFC, Axis, Kotak Q1 FY27 Margins Disappoint
On July 20, 2026, leading Indian private-sector banks fell ~5% intraday after their Q1 FY27 results (reported July 18–19) revealed sharper-than-expected net interest margin compression: HDFC Bank fell 5% (steepest intraday drop in 4 months) on a 13bp sequential NIM decline; Axis Bank dropped 5.03% on soft NII growth; Kotak fell 3.06% despite a 26% YoY net profit rise. ICICI was a relative outperformer. The Nifty Private Bank index was dragged lower; HDFC is down ~20% YTD.
Prologis's Third $18.2B Bid for Segro Just Got Rejected — What Happens Before the July 22 Takeover Panel Deadline
On July 17, 2026, Segro's board unanimously rejected Prologis's third sweetened takeover offer valued at approximately £13.5 billion ($18.16 billion), comprising £2.7 billion in cash and 0.0890 new Prologis shares per Segro share. The bid carries a 33.8% premium to Segro's June 23 closing price but was dismissed as still materially undervaluing the UK warehouse landlord. Under UK Takeover Panel rules, Prologis has until July 22, 2026 to either make a formal offer or walk away, with Bloomberg reporting a possible secondary London Stock Exchange listing as a sweetener. The proposed merger would create the world's largest industrial REIT at a time when data-center demand is reshaping the logistics property thesis.
Shein Clears Hong Kong Listing Committee at $40-50B: Fast Fashion's Biggest 2026 IPO Pivots East After the NY/London Fades
On July 17, 2026, Shein received approval from the Hong Kong Stock Exchange listing committee for its long-awaited IPO, targeting a $40-50B valuation (down from $100B in 2022). The fast-fashion retailer plans to publish its first public filing the week of July 27 and could launch the roadshow as soon as late August, after pivoting away from prior New York and London attempts. The prospectus will offer a clean read on Shein's $40B+ revenue, ~$2B net profit, supply chain, and the regulatory tradeoffs of choosing Hong Kong over U.S. listings.
2026-07-19
2026-07-18
CXMT's IPO Turns China's Memory Catch-Up Into a Direct Challenge to Micron, SK Hynix, and Samsung Electronics
China's biggest memory-chip listing in years is not just a capital-raising event. It is a signal that the memory market is being pulled into a state-backed industrial race, with consequences for pricing, capacity, and the global AI supply chain.
CXMT's Mega IPO Is Draining Liquidity From China and Repricing Hong Kong Tech
CXMT's $8.6 billion listing is not just a memory-chip event. The bigger market signal is that a giant domestic IPO can pull liquidity out of mainland China and into a policy-backed industrial story, forcing Alibaba, Tencent, and other Hong Kong tech names to reprice against a tighter cash pool.
2026-07-17
CXMT's $8.6B IPO Turns China's DRAM Catch-Up Into a Direct Challenge to Micron
China's ChangXin Memory Technologies is using a blockbuster IPO to turn AI demand into domestic DRAM capacity. That is not just a China story; it is a direct pricing challenge for Micron, SK Hynix, and Samsung Electronics.
Fifth Third's Comerica Deal Turns Regional Bank M&A Into an Expense Discipline Test
Fifth Third's second-quarter print shows how bank M&A is being judged now: not just by revenue lift, but by whether the combined platform can absorb higher technology, compensation, and integration costs without losing operating leverage.
Wall Street's Red-Hot Trading Quarter Is Really an Asia Volatility Trade
The bank earnings boom is bigger than a rate story. It is a volatility story, and increasingly an Asia story, with AI-chip flows, IPOs, and cross-border risk all feeding the same trading machine.
2026-07-16
Hyundai Motor Just Bought Boston Dynamics for the Third Time - And the 2028 IPO Math Is Now the Whole Story
Hyundai Motor Group said on July 16, 2026 that it will acquire SoftBank Group's remaining 9.65% stake in Boston Dynamics for about $325M (~₩500B), making the U.S. humanoid-robotics pioneer a wholly owned subsidiary and clearing a fast-tracked Nasdaq IPO path by 2028. The deal is the third Hyundai-Boston Dynamics transaction in five years and the first time the Korean OEM has full operational control of the robotics platform - and the read-through is direct for the entire humanoid-robotics sector (Tesla, Figure AI, Agility Robotics, Apptronik, 1X), every Korean OEM's automation strategy, and the AI capex stack that the humanoid race is now joining.
Morgan Stanley's Record Wealth Flows Turn the IPO Boom Into a Fee Machine
Morgan Stanley's second quarter showed that the bank is no longer just trading a volatile tape. It is converting IPO and M&A activity into durable wealth assets, and the scale of those inflows says the fee cycle still has room to run.
Truth API Turns Trump Media Into a Market-Data Toll Booth - and That Changes the Incentives for Anyone Trading on Truth Social
Trump Media said it will launch Truth API, a licensed real-time feed of top Truth Social accounts for financial institutions. The obvious read is monetization. The deeper read is that the company is trying to turn political attention into a data product, which creates a new market structure risk for traders who already rely on Truth Social as an information source.
2026-07-15
What to expect
Evidence-first notes with a visible point of view.
This section collects sharp takes on earnings, shareholder meetings, and market structure. Each new piece should make the thesis, the facts, and the implications obvious within the first few screens.
Expect direct analysis, not generic commentary.
Expect the data to be explicit and the argument to be easy to follow.